Ozempic könnte das Ende des Junk Food einläuten
Die Abnehmspritze Ozempic, so der Handelsname für Semaglutide, ist nicht nur eine potenziell revolutionäre Verbesserung für die Gesundheit vieler Menschen.
Sie könnte auch den Markt für Junk Food auf den Kopf stellen bzw. versenken. In den USA konsumieren 10 Prozent der Konsument:innen 60 Prozent des Junk Food.
Wer Ozempic spritzt hat weniger Appetit und kauft weniger davon:
Semaglutide has the potential to reshape the US economy, research suggests. Aljoscha Jannsen of Singapore Management University finds that sales of consumer packaged goods—processed foodstuffs, snacks, and sugary drinks, in particular—are highly susceptible to the Ozempic effect.
Janssen conducted his research using NielsenIQ’s Consumer Panel Data housed at Chicago Booth’s Kilts Center for Marketing. Analyzing 14 years of purchasing data through 2020, he finds that US households over time became more concentrated in their shopping habits. Fewer consumers accounted for an increasing share of the purchases made within different product categories. For example, in processed foods and beverages, just 10 percent of the total consumer base made more than 60 percent of all purchases on average, he finds. He deems this small group of people “over-consumers.”
The research finds a strong link between people who purchase insulin syringes, likely for use in treating diabetes, and diet pills and those in the top 10 percent of households buying unhealthy food items. Companies heavily reliant on these high-spending consumers could be at risk with the introduction of semaglutide drugs, including Ozempic.
More than 9 million Americans (about 3 percent of the population) were prescribed semaglutide medicines in the last quarter of 2022 alone, according to Trilliant Health, and J.P. Morgan Research has forecast that obesity drugs will reach an estimated 9 percent of the population by 2030.